Healthcare Sales & Marketing Network News: dopamine

Searching News Database: dopamine

HSMN NewsFeed - 27 Mar 2026
Otsuka Pharmaceutical to Acquire Transcend Therapeutics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 19 Jan 2026
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to iRegene's NouvNeu001, Making It the World's First iPSC Therapy with Both FTD and RMAT Recognitions
Regenerative Medicine Neurology FDA

HSMN NewsFeed - 20 Nov 2025
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
Biopharmaceuticals Regenerative Medicine Venture Capital

HSMN NewsFeed - 5 Mar 2025
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 14 Feb 2024
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
Regenerative Medicine Neurology Personnel

HSMN NewsFeed - 17 Nov 2022
Upstaza(TM) Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
Regenerative Medicine Neurology Regulatory

HSMN NewsFeed - 3 Nov 2022
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
Biopharmaceuticals Neurology Venture Capital

HSMN NewsFeed - 23 May 2022
MindMed Appoints Schond L. Greenway as Chief Financial Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 20 May 2022
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 Apr 2022
MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Mar 2022
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
Biopharmaceuticals Neurology Acquisitions

HSMN NewsFeed - 26 Jul 2021
BlueRock Therapeutics Announces New Board Chair, New President and CEO
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 19 Jul 2021
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease
Regenerative Medicine Neurology FDA

HSMN NewsFeed - 25 Jun 2021
Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Mar 2021
Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 22 Jan 2021
Boston Scientific Receives FDA Approval For The Vercise Genus(TM) Deep Brain Stimulation System
Devices Neurology FDA

HSMN NewsFeed - 22 Jul 2020
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 27 Apr 2020
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS(R) (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 1 Apr 2020
Aspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson Disease
Regenerative Medicine Neurology Venture Capital

HSMN NewsFeed - 12 Dec 2019
Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease
Regenerative Medicine Neurology Venture Capital

HSMN NewsFeed - 15 Nov 2019
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 Dec 2018
BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance
Biopharmaceuticals Neurology Licensing

HSMN NewsFeed - 9 Nov 2018
Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory

HSMN NewsFeed - 2 Nov 2018
BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease
Biopharmaceuticals Neurology Licensing

HSMN NewsFeed - 20 Sep 2018
BlueRock Therapeutics Appoints Shane Kovacs as Chief Business and Financial Officer
Regenerative Medicine Personnel

HSMN NewsFeed - 2 Mar 2018
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Feb 2018
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer's trials
Biopharmaceuticals Neurology

HSMN NewsFeed - 4 Jan 2018
Acacia Pharma Announces FDA Acceptance of NDA Filing For BAREMSIS(R) for the Management of Post-operative Nausea & Vomiting
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Dec 2017
Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Dec 2017
Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder
Biopharmaceuticals Neurology

HSMN NewsFeed - 21 Nov 2017
Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda(R) (Lurasidone Hydrochloride) in Europe
Biopharmaceuticals Licensing Distribution

HSMN NewsFeed - 13 Nov 2017
Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 11 Oct 2017
First Patient Treated With Titan Pharmaceuticals' Subdermal Implant For Parkinson's Disease
Biopharmaceuticals Neurology Drug Delivery

HSMN NewsFeed - 5 Oct 2017
Neurocrine Announces FDA Approval of 80 mg INGREZZA(R) (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 17 Aug 2017
BlueRock Therapeutics Expands Toronto Presence with R&D and Manufacturing Hub, Appoints Key R&D Leadership
Regenerative Medicine Personnel

HSMN NewsFeed - 7 Aug 2017
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba(TM) in Germany, France and Austria
Biopharmaceuticals Distribution

HSMN NewsFeed - 2 May 2017
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba(R) (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic Countries
Biopharmaceuticals Distribution

HSMN NewsFeed - 21 Apr 2017
Neurocrine Announces INGREZZA(TM) Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Apr 2017
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago(R) (safinamide) in Canada
Biopharmaceuticals Neurology Licensing

HSMN NewsFeed - 3 Mar 2017
Otsuka Pharmaceutical to Acquire Neurovance, Inc.
Biopharmaceuticals Neurology Mergers & Acquisitions

HSMN NewsFeed - 12 Dec 2016
Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
Regenerative Medicine Venture Capital

HSMN NewsFeed - 30 Nov 2016
Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA(TM) (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 8 Nov 2016
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave(R) (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand
Biopharmaceuticals Distribution

HSMN NewsFeed - 11 Oct 2016
Neurocrine Announces INGREZZA(TM) (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia has been Accepted for Priority Review by U.S. FDA
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 1 Sep 2016
Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 12 Aug 2016
Acacia Pharma Announces Positive Results From a Pivotal Phase 3 Trial of BAREMSIS(TM) for the Treatment of Post-Operative Nausea & Vomiting
Biopharmaceuticals

HSMN NewsFeed - 1 Aug 2016
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
Biopharmaceuticals Acquisitions Product Launch

HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 23 May 2016
Zambon Launches Xadago(R) (Safinamide) in the U.K. for Patients with Mid- to Late-Stage Parkinson’s Disease
Biopharmaceuticals Neurology Product Launch

HSMN NewsFeed - 16 Mar 2016
Allergan Announces U.S. Availability of VRAYLAR(TM) (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults
Biopharmaceuticals Product Launch

HSMN NewsFeed - 15 Mar 2016
Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE(R) in the United States
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 10 Feb 2016
Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 2 Feb 2016
Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Jan 2016
Acorda to Acquire Biotie Therapies
Biopharmaceuticals Neurology Mergers & Acquisitions

HSMN NewsFeed - 12 Jan 2016
Zambon Launches Xadago(R) (Safinamide) in Switzerland for Patients with Parkinson’s Disease
Biopharmaceuticals Neurology Product Launch

HSMN NewsFeed - 30 Dec 2015
NeuroDerm Announces Start of Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinson’s Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 3 Nov 2015
Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 20 Aug 2015
S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 15 May 2015
Zambon Launches Xadago(R) (safinamide) for Patients with Mid- to Late-Stage Parkinson’s Disease in Germany
Biopharmaceuticals Neurology Product Launch

HSMN NewsFeed - 27 Feb 2015
Chiasma Announces Completion of $70 Million Series E Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 7 Jan 2015
Mundipharma receives positive European Commission decision on Targin(R) (oxycodone/naloxone) for the treatment of Restless Legs Syndrome1
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Nov 2014
Titan Pharmaceuticals Appoints Two New Board Members
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 21 Nov 2013
Otsuka and Lundbeck's Once-Monthly Abilify Maintena(R) (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Sep 2013
Civitas Therapeutics Secures $38 Million in Financing
Biopharmaceuticals Neurology Venture Capital Personnel

HSMN NewsFeed - 23 Jul 2013
XenoPort Announces Inclusion of Horizant (Gabapentin Enacarbil) in Guidelines for Long-Term Treatment of Restless Legs Syndrome/Willis-Ekbom Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 17 May 2013
New Study Shows Effect of Neupro(R) (Rotigotine Transdermal System) on Cardiovascular Measures in Patients with Restless Legs Syndrome
Biopharmaceuticals

HSMN NewsFeed - 21 Sep 2012
Vanderbilt University and Bristol-Myers Squibb Sign Collaboration Agreement to Develop Novel Treatments for Parkinson’s Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 25 Jul 2012
NuPathe Appoints Armando Anido as Chief Executive Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 16 Jul 2012
UCB Launches Neupro(R) in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome
Biopharmaceuticals Neurology Drug Delivery

HSMN NewsFeed - 3 Apr 2012
Neupro(R) Approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 20 Mar 2012
Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
Biopharmaceuticals Neurology Licensing

HSMN NewsFeed - 28 Feb 2012
Forest Laboratories, Inc. and Gedeon Richter Plc. Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia
Biopharmaceuticals

HSMN NewsFeed - 8 Feb 2012
Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase III Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Biopharmaceuticals

HSMN NewsFeed - 26 Aug 2011
Medistem Submits Response to FDA Clinical Hold
Regenerative Medicine FDA

HSMN NewsFeed - 24 Jan 2011
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 11 Nov 2010
Ceregene Raises $11.5 Million in Series D Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 8 Nov 2010
Lilly to Acquire Avid Radiopharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 4 Nov 2010
Euthymics Bioscience, Inc. Names Biotech Executive Timothy J. Barberich to Board of Directors
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 25 Oct 2010
Omeros Receives $20 Million from Vulcan Capital and $5 Million Grant Award from Washington State's Life Sciences Discovery Fund to Advance its GPCR Program
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 10 Aug 2010
Avid Radiopharmaceuticals Expands R&D Capabilities with Appointment of Dr. Mark A. Mintun as Chief Medical Officer
Biopharmaceuticals Radiology Neurology Personnel

HSMN NewsFeed - 28 Jul 2010
Study Showed the Clinically Significant Therapeutic Benefit of Neupro(R) (rotigotine transdermal system) in the Treatment of Restless Legs Syndrome
Biopharmaceuticals

HSMN NewsFeed - 22 Jul 2010
Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 18 Jun 2010
Neupro(R) (rotigotine) significantly improved wellbeing and daily activities impaired due to limb pain associated with Restless Legs Syndrome
Biopharmaceuticals

HSMN NewsFeed - 17 Jun 2010
Neupro(R) (rotigotine transdermal system) Showed Significant Benefit on Early Morning Motor Control, Sleep and Nocturnal Symptoms in Patients With Parkinson's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 26 Apr 2010
Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa)
Biopharmaceuticals Neurology Acquisitions

HSMN NewsFeed - 23 Apr 2010
UCB Receives Complete Response Letter from U.S. FDA Regarding Neupro(R) (Rotigotine)
Biopharmaceuticals Drug Delivery Neurology FDA

HSMN NewsFeed - 13 Apr 2010
New Data Show Sustained 5-Year Benefit of Neupro(R) (Rotigotine Transdermal System) for Symptoms of Restless Legs Syndrome
Biopharmaceuticals Neurology Drug Delivery

HSMN NewsFeed - 5 Mar 2010
XenoPort Restructures to Focus on Key Programs
Biopharmaceuticals

HSMN NewsFeed - 16 Nov 2009
GSK and Nabi Announce Agreement for NicVAX(R), a Vaccine for Nicotine Addiction
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Oct 2009
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Oct 2009
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
Biopharmaceuticals Licensing

HSMN NewsFeed - 5 Oct 2009
Baxter Announces the Commercial Launch of HYLENEX at ACEP for Use in Pediatric Rehydration
Biopharmaceuticals

HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Biopharmaceuticals

HSMN NewsFeed - 8 Sep 2009
Salix Receives FDA Marketing Approval for METOZOLV ODT (Orally Disintegrating Tablets) for Relief of Diabetic Gastroparesis and Symptomatic Documented GERD
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 24 Aug 2009
Biovail to Acquire Rights to Develop, Commercialize JP-1730/Fipamezole in North America from Santhera
Biopharmaceuticals Neurology

HSMN NewsFeed - 5 Aug 2009
Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
Biopharmaceuticals Neurology

HSMN NewsFeed - 12 Jun 2009
Clinical Data Presented at International Congress Showed Treatment With Neupro(R) (rotigotine) Significantly Improved Early Morning akinesia and was Generally Well Tolerated Over Four Years
Biopharmaceuticals Neurology

HSMN NewsFeed - 29 May 2009
UCB receives CHMP positive opinion on bringing Neupro(R) back to all patients in Europe
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 18 May 2009
FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 18 May 2009
Biovail Announces Acquisition of Worldwide Rights to Tetrabenazine
Biopharmaceuticals Neurology Acquisitions

HSMN NewsFeed - 14 May 2009
Study Shows Piclozotan Improves Both Dyskinesia and OFF Time in Parkinson's Disease Patients On Levodopa Therapy
Biopharmaceuticals Neurology

HSMN NewsFeed - 13 May 2009
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Biopharmaceuticals Licensing

HSMN NewsFeed - 7 May 2009
Merck Serono Initiates SETTLE, the Second Phase III Clinical Trial of Safinamide in Advanced Parkinson's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 13 Apr 2009
XenoPort Announces Election of Co-Promotion Option for Solzira
Biopharmaceuticals

HSMN NewsFeed - 7 Apr 2009
Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States
Biopharmaceuticals

HSMN NewsFeed - 26 Mar 2009
Neuraltus Pharmaceuticals Raises $17 Million Series A Funding
Biopharmaceuticals Neurology Venture Capital

HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Feb 2009
Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
Biopharmaceuticals Neurology

HSMN NewsFeed - 1 Dec 2008
Cambridge Laboratories Announces Launch of XENAZINE(R) (Tetrabenazine) in the US
Biopharmaceuticals Neurology

HSMN NewsFeed - 8 Oct 2008
Circassia Acquires North American and Japanese Rights to Dopexamine
Biopharmaceuticals

HSMN NewsFeed - 17 Sep 2008
Cambridge Laboratories Announces New Marketing Arrangements for XENAZINE(R) in North America
Biopharmaceuticals Neurology

HSMN NewsFeed - 16 Sep 2008
GSK and XenoPort Announce Submission of New Drug Application Requesting FDA Approval of Solzira(TM) for Restless Legs Syndrome
Biopharmaceuticals

HSMN NewsFeed - 18 Aug 2008
Cambridge Laboratories Announces FDA Approval of XENAZINE(R) (tetrabenazine) in the US
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 15 Aug 2008
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 13 Jul 2008
Neurogen Announces Suspension of Insomnia Study with Adipiplon
Biopharmaceuticals

HSMN NewsFeed - 13 Jun 2008
U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 10 Jun 2008
New Data Shows Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Limb Pain in Patients With Restless Legs Syndrome (RLS)
Biopharmaceuticals

HSMN NewsFeed - 15 May 2008
Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Apr 2008
Neupro(R) recommended for approval in Europe for Restless Legs Syndrome
Biopharmaceuticals Regulatory

HSMN NewsFeed - 22 Apr 2008
Pfizer Japan to Launch Champix(R) the First Prescription Oral Smoking Cessation Aid in Japan
Biopharmaceuticals

HSMN NewsFeed - 17 Apr 2008
Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Biopharmaceuticals Diagnostics Neurology

HSMN NewsFeed - 11 Apr 2008
Status of the E2007 (perampanel) Development Program - Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications
Biopharmaceuticals

HSMN NewsFeed - 31 Mar 2008
ACADIA Pharmaceuticals Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
Biopharmaceuticals

HSMN NewsFeed - 29 Feb 2008
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Feb 2008
XenoPort and GlaxoSmithKline Report Positive Top-Line Results of Final Pivotal Trial of XP13512/GSK1838262 for Restless Legs Syndrome
Biopharmaceuticals

HSMN NewsFeed - 18 Feb 2008
Solvay Pharmaceuticals, Inc. Receives Fast Track Designation From U.S. Food and Drug Administration for Levodopa/Carbidopa Intestinal Gel for Advanced Parkinson's Disease
Biopharmaceuticals FDA Neurology

HSMN NewsFeed - 22 Jan 2008
Knopp Neurosciences Completes First Series B Financing of $10 Million
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 8 Jan 2008
Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
Biopharmaceuticals

HSMN NewsFeed - 13 Dec 2007
Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 13 Dec 2007
Neupro(R) Filed with the FDA for the Treatment of Restless Legs Syndrome
Biopharmaceuticals Neurology

HSMN NewsFeed - 5 Dec 2007
Neupro(R) Filed in Europe for the Treatment of Restless Legs Syndrome
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Nov 2007
Yaupon Therapeutics Closes $14.5 Million Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 20 Nov 2007
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Nov 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Nov 2007
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Oct 2007
Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
Biopharmaceuticals FDA Neurology

HSMN NewsFeed - 8 Oct 2007
Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
Biopharmaceuticals Neurology Drug Delivery

HSMN NewsFeed - 8 Oct 2007
Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease
Biopharmaceuticals Neurology Drug Delivery

HSMN NewsFeed - 3 Oct 2007
Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 27 Sep 2007
Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Sep 2007
Valeant Pharmaceuticals Announces the Launch of the zelaCARD for Parkinson's Disease Patients Taking Zelapar(R)
Biopharmaceuticals Neurology

HSMN NewsFeed - 10 Sep 2007
Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 30 Aug 2007
Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Aug 2007
Prestwick Pharmaceuticals, Inc. Strengthens Management Team with Appointment of Robert S. Radie as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Aug 2007
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Aug 2007
Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc. Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Jul 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Jul 2007
UCB Announces the U.S. Launch of Neupro(R) (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 16 Jul 2007
SCHWARZ PHARMA and UCB, Inc. Announce U.S. Launch of Neupro(R) (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Jun 2007
Titan Annnounces Completion of Patient Enrollment in Randomized Phase IIb Clinical Study of Spheramine(R) In Parkinson's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 22 Jun 2007
TransOral Pharmaceuticals, Inc. Changes Name to Transcept Pharmaceuticals, Inc.
Biopharmaceuticals

HSMN NewsFeed - 21 Jun 2007
Ceregene and Genzyme Announce Partnership for the Development and Commercialization of Cere-120 for Parkinson's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Jun 2007
Imaging Agent from Avid Radiopharmaceuticals to Be Licensed by Bayer Schering Pharma for Early Detection of Alzheimer's Disease
Biopharmaceuticals Radiology

HSMN NewsFeed - 10 May 2007
FDA Approves SCHWARZ PHARMA's Neupro(R) (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease in USA
Biopharmaceuticals Drug Delivery Neurology FDA

HSMN NewsFeed - 8 May 2007
Biogen Idec and Vernalis Plc Announce the Start of Phase II Program of BIIB014 in Parkinson's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 27 Apr 2007
Baxter Introduces HYLENEX for Use in Ophthalmic Surgery
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 16 Apr 2007
SCHWARZ PHARMA Announces Publication of Rotigotine Data for Advanced Parkinson's Disease in Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 13 Apr 2007
Ceregene Enrolling Patients for Phase 2 Clinical Trial of Parkinson's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 2 Apr 2007
Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa
Biopharmaceuticals Neurology

HSMN NewsFeed - 29 Mar 2007
FDA Announces Voluntary Withdrawal of Pergolide Products
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 22 Mar 2007
Avicena Announces Patient Enrollment in National Institutes of Health (NIH) Phase III Parkinson's Disease Trial
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Mar 2007
Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimer's Disease Presented at AD/PD Meeting
Biopharmaceuticals Radiology Neurology

HSMN NewsFeed - 14 Feb 2007
Halozyme Therapeutics and Baxter Present Promising Results for the Use of HYLENEX From the Infuse-Morphine Study
Biopharmaceuticals

HSMN NewsFeed - 14 Feb 2007
Halozyme and Baxter Expand Global HYLENEX Collaboration
Biopharmaceuticals

HSMN NewsFeed - 24 Jan 2007
Proneuron Announces the Receipt of a $430,000 Grant from the Michael J. Fox Foundation to Develop Its PN277 for the Treatment of Parkinson's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Jan 2007
Wyeth and Solvay Enter Into an Additional Neuroscience Collaboration
Biopharmaceuticals

HSMN NewsFeed - 3 Jan 2007
SCHWARZ PHARMA Announces Publication of Rotigotine Data in Neurology
Biopharmaceuticals Drug Delivery Neurology

HSMN NewsFeed - 12 Dec 2006
ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available
Biopharmaceuticals

HSMN NewsFeed - 7 Dec 2006
ABILIFY(R) (aripiprazole) Demonstrated Efficacy as Long-Term Maintenance Therapy in Adults With Bipolar I Disorder Following Treatment for a Recent Manic Or Mixed Episode
Biopharmaceuticals

HSMN NewsFeed - 6 Dec 2006
Bifeprunox Showed Improvement of Symptoms and Maintenance of Stability with Fewer Metabolic Side Effects vs. Placebo in Patients with Schizophrenia
Biopharmaceuticals

HSMN NewsFeed - 6 Dec 2006
Avicena Signs Agreement with the National Institute of Neurological Disorders and Stroke for Phase III Trial for Novel Parkinson's Disease Candidate
Biopharmaceuticals Neurology

HSMN NewsFeed - 6 Dec 2006
Phase 2 and 3 Clinical Data for Bifeprunox in Patients With Schizophrenia Showed Improvement of Symptoms and Maintenance of Stability With Fewer Metabolic Side Effects Versus Placebo
Biopharmaceuticals

HSMN NewsFeed - 28 Nov 2006
Neurogen In-licenses Drug Candidate for Parkinson's Disease and Restless Legs Syndrome
Biopharmacetuicals Licensing

HSMN NewsFeed - 24 Oct 2006
Stem Cell Treatment Proven to Reduce Parkinson's Symptoms
Regenerative Medicine Neurology

HSMN NewsFeed - 22 Oct 2006
OREXIGEN(TM) Therapeutics Reports Positive Phase II Results for Excalia(TM) Combination-Therapy to Treat Obesity
Biopharmaceuticals

HSMN NewsFeed - 16 Oct 2006
Serono and Newron Announce Global Development and Commercialization Agreement for Safinamide
Biopharmaceuticals Neurology Licensing

HSMN NewsFeed - 11 Oct 2006
Osta Announces Promising Clinical Results on Blood Tests for Parkinson's Disease & Alzheimer's Disease
Diagnostics Neurology

HSMN NewsFeed - 10 Oct 2006
DOV Pharmaceutical, Inc. Announces New Strategic Direction, Bicifadine Clinical Studies Results and Program Updates
Biopharmaceuticals

HSMN NewsFeed - 25 Sep 2006
Boston Life Sciences, Inc. Announces Findings from Review of POET-1 Study of ALTROPANE(R) Molecular Imaging Agent
Biopharmaceuticals Radiology Neurology

HSMN NewsFeed - 18 Jul 2006
Valeant Pharmaceuticals Announces Availability of Zelapar(R) for Parkinson's Disease Patients
Biopharmaceuticals Drug Delivery Neurology

HSMN NewsFeed - 27 Jun 2006
Halozyme and Baxter Announce Availability of Hylenex for Subcutaneous Delivery of Medications and Fluids
Biopharmaceuticals

HSMN NewsFeed - 26 Jun 2006
Wythe Therapeutics and VeroScience Announce Worldwide License for Cycloset(R)
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 17 May 2006
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 17 May 2006
Amarin Acquires Parkinson's Disease Drug Candidate
Biopharmaceuticals Neurology Acquisitions

Return to NewsFeed

Additional items found! 107

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 107 additional stories matching:
dopamine
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!